Introduction
============

Hepatocellular carcinoma (HCC) is the one of the most common malignancy in the world ([@B1]). It usually occurs following previous liver disease, such as chronic hepatitis B or C and liver cirrhosis (LC) ([@B2]). Most HCCs develop following by chronic liver diseases ([@B3]). Multiple factors such as genetic and epigenetic changes have been reported in HCC patients ([@B4]). cDNAmicroarray studies were designed to identify abnormally expressed gene sets for HCC ([@B5]-[@B7]). On the other hand, some studies have been surveyed proteomic profile of HCC patients and have been introduced some new biomarkers ([@B8]). Many polymorphisms alter biologic pathways of carcinogenesis, including inflammation (IL1B, TNFA and TGF) ([@B9], [@B10]); oxidative stress (SOD2, MPO) ([@B11], [@B12]); DNA repair (MTHFR, XRCC3) ([@B13], [@B14]) and cell cycle (MDM2) ([@B15]) and TP53 ([@B16]). At least, in half of HCC patients the P53 cell cycle pathway alters with frequent TP53 mutations (12%- 48%) ([@B17]-[@B19]). Apart from genetic aberrations, alterations in protein expression have been reported such as Alpha- Fetoprotein (AFP), Des-Gamma-Carboxy (Abnormal), Prothrombin (DCP), Transforming Growth Factor-Beta (TGF-Beta), Serum Alpha-1-Fucosidase, Human Carbonyl Reductase 2, Tumor-Specific Growth Factor (TSGF), and Epidermal Growth Factor Receptor Family (EGFR) ([@B20]). At present, diagnostic methods included alpha-fetoprotein (AFP) and magnetic resonance imaging (MRI). Currently, the accepted biomarker for diagnosis of HCC is AFP; But the sensitivity and specificity of this agent are not satisfactory ([@B21], [@B22]). On the other way, most patients often have advanced in stage of disease at the time of diagnosis because the lack of special sign ([@B23]). Hence, there is an urgent demand to find specific biomarkers of HCC, which can be used specifically and sensitively in diagnosis as well as in prognosis and therapeutic evaluation. Liver cirrhosis (LC) and its associated complications are introduced as essential factors in morbidity and mortality worldwide ([@B24], [@B25]). The diagnostic methods of cirrhosis are based on the combined results of clinical and imaging examinations ([@B24]). Clinical symptoms and laboratory data of liver diseases frequently overlap; thus interpretation a differential diagnosis is difficult ([@B26]). Liver biopsy, is performed in patients with ambiguous diagnostic results. But this way is an invasive method which imposes pain to patients. For this, a non-invasive method for early diagnosis of hepatic fibrosis is needed. Some genetic liver disease that predispose to early cirrhosis with related mutations have been reported. Cystic fibrosis by altering activity of CFTR, Wilson disease by increased levels the ATP7B, hereditary hemochromatosis by iron-induced lipid peroxidation causes hepatocellular injury, Glycogen storage disease type IV by The altered stored glycogen impairs the osmotic pressure within the hepatocyte and Cholesteryl ester storage disease by Accumulation of cholesteryl are the known ones ([@B26]). Since the biological heterogeneity of liver diseases, it is difficult to distinguish HCC and other liver diseases such as cirrhosis or fatty liver, simply by the clinical symptoms or pathophysiological characteristics ([@B27]). Ideally, for timely treatment, the biomarker(s) that could recognize the fibrosis in the early stages of hepatic disorder to prevent the progression of cirrhosis to HCC is required ([@B28]). Interaction networks might give information of the functions of newly discovered proteins ([@B29]-[@B31]). The protein network analysis provides a scientific model that improves understanding of the mechanisms underlying human diseases ([@B32]-[@B38]). The centralized applications of PPI networks to disease addition to the identification of genes and proteins associated with diseases turn around on the study of network properties to find their relation to disease states. Classification of network- based disease and the identification of disease-related sub networks are another applications of the PPI network ([@B39]). Our goal is to present the PPI of cirrhosis and HCC patients versus healthy control group and comparison with each other to find common and sensitive points to introduce possible biomarker (s) in these diseases development and subsequently drug target discovering. This investigation was designed based on proteomic studies in cirrhosis and HCC patients published since 1997.

Material and Methods
====================

**Data Collection**

In this study, the inclusion criteria were the proteomic studies on the human species involved in the comparison between the serum or plasma of patients (cirrhosis or hepatocellular carcinoma) and healthy control. Exclusion criteria were the studies on non-human sample and the studies on samples of tissue or cell lines, saliva, CSF, and urine. It has also been eliminated the papers which were compared serum or plasma of patients with the groups except healthy control. There was no limitation in methods in proteomic study. A number of 73 papers about HCC and cirrhosis proteomic profiling were reviewed. We manually evaluated the publications and it was selected the articles in line with the above conditions. Duplicated proteins and genes were eliminated. Finely, 29 genes for cirrhosis and 63 genes for HCC were extracted. Genes and proteins were presented in [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Uniprot accession number of selected genes were retrieved from web site (uniprot.org).

**Protein-Protein Interaction Analysis**

PPI network is the basic skeleton for proteins to determine their functions in the system biology ([@B40]). Specialization the interactions of proteins in a given proteome could reveal the biochemistry of the cell ([@B41]). It also helps in the identification of drug targets by introducing hubs ([@B42]). The PPI network was visualized using the Cytoscape 3.2.1 software. MINT, Reactome-FLs, databases were used for this topology visualization. We used Molecular Complex Detection (MCODE) to analyze the characteristics of the networks. The MCODE clusters was based on the topology to find the densely connected region. Gene ontology categories were analyzed to identify the function of each highly connected region that was generated by the MCODE. These include Kappa statistic ≥ 0.5, enrichment and Bonferroni step down method for probability value correction ([@B43]). The degree of functional enrichment for a given cluster was quantitatively assessed (P-value) using the ClueGO tool ([@B44]). ClueGO integrates gene ontology (GO) terms and creates a functionally organized GO/pathway term network. It can analyze genes and comprehensively visualizes functionally grouped terms ([@B45]).

###### 

A number of genes in cirrhosis derived from articles include of serum proteomic profile

  Protein name(references)                        Uniprot code   Gene name   Protein name(references)                               Uniprot code   Gene name
  ----------------------------------------------- -------------- ----------- ------------------------------------------------------ -------------- -----------
  ApolipoproteinA-1([@B47])                       P02647         APOA1       apolipoprotein E([@B46])                               P02649         APOE
  Haptoglobin([@B48])                             P00738         HP          C4b-binding protein ([@B46])alpha chain                P04003         C4BPA
  Alpha1-Antitrypsin([@B28])                      P01009         SERPINA1    Glutathione peroxidase 3([@B46])                       P22352         GPX3
  Ceruloplasmin([@B49])                           P00450         CP          Beta-2-glycoprotein 1([@B28])                          P02749         APOH
  Transthyretin([@B50])                           P02766         TTR         complement component 4B([@B46])                        P0C0L5         C4B
  glycoprotein 1([@B46], [@B50])                  P02750         LRG1        Zinc-2-glycoprotein([@B28])                            P25311         AZGP1
  Complement factor H-related protein 1([@B28])   Q03591         CFHR1       Immunoglobulin gamma-2-chainc([@B50])                  P01859         IGHG2
  Apolipoprotein L1([@B51])                       O14791         ApoL1       complement factor B([@B46])                            P00751         CFB
  Transgelin ([@B28])                             Q01995         TAGLN       complement component 4A([@B46])                        P0C0L4         C4A
  Paraoxonase/ arylesterase 1([@B46])             P27169         PON1        amyloid P component([@B46])                            P02743         APCS
  alpha-1-microglobulin/ bikunin ([@B46])         P02760         AMBP        Inter-alpha-trypsin inhibitor heavy chain H4([@B28])   Q14624         ITIH4
  haptoglobin-related protein([@B46])             P00739         LRG         Complement C3([@B28])                                  P01024         C3
  Hemopexin([@B50])                               P02790         HPR         1 antichymotrypsin([@B46]) α                           P01011         SERPINA3
  α-1 acid glycoprotein([@B50])                   P02763         ORM1        CD5-like antigen([@B50])                               O43866         CD5L
                                                                             clusterin([@B50])                                      P10909         CLU

###### 

A number of genes in hepatocellular carcinoma derived from articles include of serum proteomic profiling

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein name(references)                              Gene name   Uniprot code    Protein name(references)                                                 Gene name       Uniprot code
  ----------------------------------------------------- ----------- --------------- ------------------------------------------------------------------------ --------------- ---------------
  Annexin A6([@B53])                                    ANXA6       P08133          Mannose receptor, C type 1-like 1([@B52])                                MRC1L1          B9EJA8

  Complement component 9 ([@B53])                       C9          P02748          Vascular cell adhesion protein 1([@B52])                                 VCAM1           E9PDD2

  Ceruloplasmin([@B53])                                 CP          P00450          Fibrinogen β chain, isoform CRA_e([@B52])                                FGB             D3DP13

  serum amyloid A4([@B53])                              SAA4        P35542          Proteinase 3([@B52])                                                     PRTN3           D6CHE9

  serum amyloid A2([@B53])                              SAA2        P0DJI9          Hemoglobin delta-beta fusion protein([@B52])                             HBD/HBB         Q5XTR9

  Transthyretin([@B52], [@B54])                         TTR         P02766          Polymeric immunoglobulin                                                 PIGR            P01833

  Clusterin([@B54])                                     CLU         P10909          receptor([@B52])\                                                        FOSL2           C9JCN8
                                                                                    Fos-related antigen 2([@B52])                                                            

  haptoglobin α2 chain([@B54])                          HP          P00738          Cyclin-dependent kinase-like 1([@B52])                                   CDKL1           Q00532

  heat-shock protein 27([@B55]) α-fetoprotein([@B52])   Hsp27       P04792          cytoskeleton-associated protein5([@B52])                                 CKAP5           Q14008

  Apolipoprotein A-I ([@B46])                           AFP APOA1   P02771 P02647   Transferrin receptor protein 1 ([@B52]) Transmembrane protein 200C(52)   TFRC TMEM200C   P02786 A6NKL6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![This figure shows a PPI network, which consists of 651 nodes and 1305 edges for cirrhosis (a) and 2024 nodes and 3817edges for HCC (b). The highlighted nodes APOE, TTR, CLU related to cirrhosis and TTR CLU, APOA1, TFRC, VWF, CKAP 5, A2M, ZNF648, CASP8, HSP27 for hepatocellular carcinoma](GHFBB-S14-g001){#F1}

![Mapping degree and betweenness parameters of candidate protein interaction network to node size and color; (a) cirrhosis patients and (b) HCC patients. More details are accessible in the text](GHFBB-S14-g002){#F2}

Results
=======

Twenty-nine ([@B29]) genes in cirrhosis and sixty-three ([@B63]) genes in HCC with differential gene expression were distinguished via literature survey. Genes and proteins were presented in [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} for cirrhosis liver and HCC respectively. Hub is a node with a number of links that greatly exceeds the average ([@B57]). Cytoscape analysis revealed a great number of close interconnections that can be seen in [Figure 1](#F1){ref-type="fig"} (a for cirrhosis liver and b related to HCC). Based on degree values, about 15% of the initial proteins are selected as hub proteins. APOE, TTR, CLU and APOA1 as related hub proteins of cirrhosis and TTR, CLU, APOA1, TFRC, VWF, CKAP5, A2M, ZNF648, mCASP8, HSP27 as hub proteins of HCC are highlighted in [figure 1](#F1){ref-type="fig"} and tabulated in [table 3](#T3){ref-type="table"}. In [figure 2](#F2){ref-type="fig"} is represented based on the node size and color changes of the nodes. As the circles get bigger and their color change from green to red, their value of the degree and the betweenness centrality increase. The related subnetworks were introduced by MCODE ([figure 4](#F4){ref-type="fig"}). Among the genes that involved in cirrhosis, APOE determined as seed while genes of HCC have no seed. ClueGo is also a Cytoscape software for gene ontology and pathway enrichment analysis. The analyzed results of MCODE by ClueGo for biological process is shown in [figure 4](#F4){ref-type="fig"}.

###### 

A number of genes with significant centrality value derived from figure 1, a for cirrhosis liver and b is related to HCC, based on two fundamental centrality properties analysis (Degree and Betweeness centrality

           **Unipr** **otcode**   **Gene** **name**   **Degree**   **Betweenness** **centrally**
  -------- ---------------------- ------------------- ------------ -------------------------------
  a        P02647                 APOA1               238          0.43889
  P10909   CLU                    216                 0.319182     
  P02766   TTR                    136                 0.142145     
  P02649   APOE                   131                 0.165061     
  b        **Uniprotcode**        **Gene name**       **Degree**   **Betweenness centrally**
  P04792   HSP27                  846                 0.444179     
  Q14790   CASP8                  544                 0.162997     
  Q5T619   ZNF648                 400                 0.361564     
  Q14008   CKAP5                  271                 0.19395      
  P02647   APOA1                  238                 0.159222     
  P01023   A2M                    230                 0.131263     
  P10909   CLU                    216                 0.101279     
  P02786   TFRC                   146                 0.076278     
  P04275   VWF                    146                 0.093813     
  P02766   TTR                    136                 0.040481     

![MCODE algorithm analysis demonstrates clusters based on the number of interconnections in the large network of protein-protein interactions for (a) cirrhosis disease and (b) HCC disease](GHFBB-S14-g003){#F3}

Discussion
==========

The importance of human molecular interaction networks no summarized only in reveals protein function with their inter- relationships, even its clear view of fundamental human biology as well as disease progression, diagnosis, and treatment ([@B58]).

The protein Networks analysis provides a model that elevates systems-level understanding of the mechanisms of diseases ([@B59], [@B60]) to analyze therapeutic drugs and their targets ([@B61]-[@B63]) and discovering the novel network-based biomarkers ([@B64]). In this study, protein network of HCC and cirrhosis patient has investigated. This analysis can lead to figure out a better understanding of the etiology of both liver disease and the specified pattern of gene expression in cirrhosis and HCC. On the other hand, therapeutic targets and diagnostic biomarkers can be accelerated by targeting the specific hub genes. Previous studies introduced cirrhosis as one of the reasons in HCC development ([@B65]) then finding molecular common points to be expected between two diseases. The importance of PPI analysis has been reported in cancer related genes ([@B34], [@B36]). Hub genes have virtual conception to study due to their centrality role in a PPI network ([@B66]). As represented in [figure 1](#F1){ref-type="fig"}, protein interaction networks of HCC and cirrhosis are made up of numerous nodes that provide hub selection. APOE, TTR, CLU and APOA1 as hub protein are introduced for cirrhosis and TTR, CLU, APOA1, TFRC, VWF, CKAP5, A2M, ZNF648, CASP8 and HSP27 (HSPB1) are the related hub proteins to HCC. The all introduced hub proteins (except TTR for HCC) are bottlenecks (cut off 0.05 is used for betweenness centrality). APOA1 and CLU are the two hub-bottlenecks common between the two diseases. As it is presented in the [table 3](#T3){ref-type="table"}, APOA1 and CLU are characterized by the most values of degree and betweenness centralities for cirrhosis. ApoA1 is the main protein component of high density lipoprotein in plasma, which is involved in the formation of most plasma cholesterol esters ([@B67]) .This protein potently suppresses tumor growth and metastasis in multiple animal tumor models ([@B68]) . The validated changes of expression of APOA1 accompanied by a few proteins have the potential for development into high-performance tests used in the diagnosis and or monitoring of HCC and LC patients ([@B46]). CLU is a Golgi molecular chaperone involved in BAX- antiapoptotic processes, activation of the phosphatidylinositol 3-kinase/ protein kinase B pathway, promotion of angiogenesis, mediation of the nuclear factor kappa B (NF-κB) pathway and modulation of extra-cellular signal-regulated kinase (ERK) signaling. A number of biological processes, including programmed cell death (Down regulation allows for p53activation and cell death), lipid transport, membrane recycling and cell adhesion ([@B69], [@B70]). Serum clusterin was introduced as more specific and sensitive biomarker than AFP in distinction of HBV-cirrhosis with HCC base on HBV-cirrhosis ([@B71]). It also has been shown that clusterin may be a useful marker in the evaluation of prognosis of patients with alcoholic cirrhosis and severity of liver disease ([@B72]). CLU involved in BAX- antiapoptotic processes and it's down regulation allows p53 activation and cell death ([@B73]). MCODE clustering algorithm (center based) demonstrates the possible presence of similar functional protein in the two PPI networks. As it is shown in [figure 3](#F3){ref-type="fig"} there are 2 clusters for the two PPI networks that are approximately similar. The PPI network in HCC has no seed, but in cirrhosis C4BPA is introduced as seed protein. More information about the roles of the 2 clusters in the biological processes is presented in [figure 4](#F4){ref-type="fig"}. ClueGo provided functional annotation (BP) of the studied modules. Biological process analysis revealed some similarities between the two diseases. The significant role of the immune system and a few common pathways show the closeness of the two diseases. Some of the important proteins are involved in the terms. The highlighted roles of APOA1 in the revers cholesterol transport pathway and CLU in positive regulation of neurofibrillary tangle assembly pathway in the two major pathways of studied diseases are identified. CLU is related to reverse cholesterol transport, platelet degranulation and human immune response pathways. However, APOA1 is involved in reverse cholesterol transport, platelet degranulation and humoral immune response negative regulation of immune effector process pathways.

![Functional distribution of biological process of modules of (a) cirrhosis and (b) HCC (b) (*P*\<0.05). These include Kappa statistic ≥ 0.5, enrichment and Bonferroni step down method for probability value correction. The stars show the pathways with P-value \<0.05. The pathways with two stars have more significant score rather than one star](GHFBB-S14-g004){#F4}

Protein-protein interaction analysis and pathway assessment showed a closed molecular relationship between cirrhosis and HCC. The finding pointed to the significant role of APOA1 and CLU as the common two biomarker in development of cirrhosis and HCC diseases.

This research has been derived from the PhD. thesis of Akram Safaei.
